Company news
Kalaris Therapeutics, Inc. news in 2022
Kalaris Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 14, 2022
AlloVir Reports Third Quarter 2022 Financial Results
November 2, 2022
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
August 30, 2022
AlloVir Announces $126.6 Million Registered Direct Offering
July 26, 2022
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
June 6, 2022
AlloVir Appoints Shawn Tomasello to Its Board of Directors
March 30, 2022
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
February 9, 2022
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation
January 4, 2022
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 2, 2022